Viread, illustration of tablet form (not a photo of the actual pack)

Illustrative image.

Viread

Tenofovir Disoproxil

Prescription required

$2514.00

245mg · 3 × 30 tablets · 3 months supply

BrandBranded medicine· By Gilead SI

$838.00 per month

How long a supply?

1 month$838.00 a month
3 months$838.00 a month
6 months$838.00 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$10056a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningPosttreatment acute exacerbation of hepatitis b

Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted

Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely in HBV-infected patients who discontinue VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Read this with the rest of the clinical information

About Viread

Overview

Viread is an antiviral medicine containing tenofovir disoproxil fumarate. It is used with other antiretroviral medicines to treat HIV-1 infection and is also used to treat chronic hepatitis B. It works by blocking reverse transcriptase, an enzyme used by HIV-1 and the hepatitis B virus to multiply.

What it treats

- HIV-1 infection, in combination with other antiretroviral medicines, in adults and children aged 2 years and older who weigh at least 10 kg. - Chronic hepatitis B in adults and children aged 2 years and older who weigh at least 10 kg.

Safety information

Side effects

Common side effects reported in adults with HIV include rash, diarrhoea, nausea, headache, pain, depression and weakness. In people with hepatitis B and compensated liver disease, nausea was the most common side effect. In those with decompensated liver disease, common side effects included abdominal pain, nausea, difficulty sleeping, itching, vomiting, dizziness and fever. Side effects in children were consistent with those seen in adults. Serious side effects that warrant contacting a doctor include new or worsening kidney problems, including acute kidney failure and Fanconi syndrome; severe worsening of hepatitis B; loss of bone mineral density and problems with bone mineralisation; immune reconstitution syndrome, which may need further assessment and treatment; and lactic acidosis (a build-up of lactic acid in the blood) or severe liver enlargement with fat accumulation.

FDA boxed warning

Posttreatment acute exacerbation of hepatitis b

Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted

Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely in HBV-infected patients who discontinue VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

Before taking this medicine

The supplied FDA label lists no contraindications for Viread. However, important precautions apply: Viread can cause new or worsening kidney problems, including acute kidney failure and Fanconi syndrome. Avoid use with medicines that can damage the kidneys, including those used recently. People with hepatitis B should be offered HIV antibody testing before starting Viread. In people with HIV, with or without hepatitis B, Viread should only be used as part of an appropriate combination HIV treatment regimen. Bone mineral density may decrease. Bone density assessment should be considered for people with a history of fractures caused by weakened bones or other risk factors for osteoporosis or bone loss. Immune reconstitution syndrome, an inflammatory response as the immune system recovers, may require further assessment and treatment. Treatment should be stopped if symptoms or laboratory findings suggest lactic acidosis (a build-up of lactic acid in the blood) or significant liver toxicity. Breastfeeding is not recommended for mothers with HIV-1 because of the potential for HIV-1 transmission.

Interactions

Tell your doctor if you take didanosine, atazanavir, other HIV-1 protease inhibitors or medicines for hepatitis C. Viread can increase didanosine levels, so your doctor may need to adjust your treatment and monitor closely for toxicity. Viread can lower atazanavir levels; the label specifies that atazanavir must be given with ritonavir when used with Viread. Certain HIV-1 protease inhibitors and hepatitis C medicines can increase tenofovir levels. Your doctor should monitor for signs of tenofovir toxicity if these medicines are used together.

Using Viread

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VIREAD (TENOFOVIR DISOPROXIL FUMARATE) TABLET, COATED VIREAD (TENOFOVIR DISOPROXIL FUMARATE) POWDER [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).

Patient information and references

Official and supporting information to read alongside advice from your prescriber or pharmacist.

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines